Management of Graves Thyroidal and Extrathyroidal Disease: An Update

George J Kahaly, George J Kahaly

Abstract

Context: Invited update on the management of systemic autoimmune Graves disease (GD) and associated Graves orbitopathy (GO).

Evidence acquisition: Guidelines, pertinent original articles, systemic reviews, and meta-analyses.

Evidence synthesis: Thyrotropin receptor antibodies (TSH-R-Abs), foremost the stimulatory TSH-R-Abs, are a specific biomarker for GD. Their measurement assists in the differential diagnosis of hyperthyroidism and offers accurate and rapid diagnosis of GD. Thyroid ultrasound is a sensitive imaging tool for GD. Worldwide, thionamides are the favored treatment (12-18 months) of newly diagnosed GD, with methimazole (MMI) as the preferred drug. Patients with persistently high TSH-R-Abs and/or persistent hyperthyroidism at 18 months, or with a relapse after completing a course of MMI, can opt for a definitive therapy with radioactive iodine (RAI) or total thyroidectomy (TX). Continued long-term, low-dose MMI administration is a valuable and safe alternative. Patient choice, both at initial presentation of GD and at recurrence, should be emphasized. Propylthiouracil is preferred to MMI during the first trimester of pregnancy. TX is best performed by a high-volume thyroid surgeon. RAI should be avoided in GD patients with active GO, especially in smokers. Recently, a promising therapy with an anti-insulin-like growth factor-1 monoclonal antibody for patients with active/severe GO was approved by the Food and Drug Administration. COVID-19 infection is a risk factor for poorly controlled hyperthyroidism, which contributes to the infection-related mortality risk. If GO is not severe, systemic steroid treatment should be postponed during COVID-19 while local treatment and preventive measures are offered.

Conclusions: A clear trend towards serological diagnosis and medical treatment of GD has emerged.

Keywords: Graves disease; TSH receptor antibodies; antithyroid drugs; diagnosis; management; radioactive iodine; thyroidectomy; treatment.

© The Author(s) 2020. Published by Oxford University Press on behalf of the Endocrine Society.

Figures

Figure 1.
Figure 1.
Algorithm for the management of Graves hyperthyroidism. TSH-R-Ab, thyrotropin receptor antibodies; FT4, free thyroxine; T3, triiodothyronine; scan, thyroid scintigraphy; MMI, Methimazole; RAI, radioactive iodine; TX, total thyroidectomy; GO, Graves orbitopathy; mo., months.
Figure 2.
Figure 2.
(A) Sites of action of novel treatments for Graves hyperthyroidism. Four (I-IV) mechanisms of action are represented. (I) K1-70 is a human anti-TSH-R blocking mAb. (II) Iscalimab is an anti-CD40 mAb blocking CD40-CD40 ligand (CD154) costimulatory pathway. (III) ATX-GD-59 is an “apitope” restoring immune tolerance to the TSH-R. (IV) Rituximab is an anti-CD20 Mab that inhibits B-cells and reduces autoantibody production. (B) Sites of action of novel treatments for Graves orbitopathy. Seven (I-VII) mechanisms of action are represented. (I) Mycophenolate has a dual antiproliferative effect on B and T cells. (II) Anticytokine therapies inhibit inflammatory molecules, for example, proinflammatory cytokines, chemoattractants, adhesion molecules, growth factors, etc., and include an anti-IL-6R mAb, tocilizumab, as well as anti-TNFα Ab. (III and IV) B cell targeting therapies include rituximab, an anti-CD20 mAb causing B cell depletion, and an anti-BAFF mAb (belimumab) preventing BAFF from interacting with its receptors. (V) Teprotumumab, an anti-IGF-1R mAb blocking the activation of orbital target cells (fibroblasts) with subsequent excess release of hydrophilic acidic mucopolysaccharides (GAG) and signaling of IGF-1R has been recently cleared by the FDA. (VI) K1-70 is an anti-TSH-R mAb blocking TSH-R activation by stimulatory TSH-R-Ab. (VII) Small molecules bind to the transmembrane domain of the TSH-R blocking its activation. mAb, monoclonal antibody; BAFF, B cell activating factor; CD40L, CD40 ligand; IGF-1R, insulin-like growth factor-1 receptor; IL-6R, interleukin-6 receptor; TNFα, tumor necrosis factor-α; TSH-R, thyrotropin receptor; TSH-R-Ab, thyrotropin receptor antibody; MHC class II, major histocompatibility class II molecule.

References

    1. Bahn Chair RS, Burch HB, Cooper DS, et al. ; American Thyroid Association; American Association of Clinical Endocrinologists . Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593-646.
    1. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association Guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J. 2018;7(4):167-186.
    1. Bartalena L. Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol. 2013;9(12):724-734.
    1. Nyström HF, Jansson S, Berg G. Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005. Clin Endocrinol (Oxf). 2013;78(5):768-776.
    1. McLeod DS, Caturegli P, Cooper DS, Matos PG, Hutfless S. Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. JAMA. 2014;311(15):1563-1565.
    1. Dittmar M, Libich C, Brenzel T, Kahaly GJ. Increased familial clustering of autoimmune thyroid diseases. Horm Metab Res. 2011;43(3):200-204.
    1. Frommer L, Kahaly GJ. Autoimmune polyendocrinopathy. J Clin Endocrinol Metab. 2019;104(10):4769-4782.
    1. Kahaly GJ, Frommer L. Polyglandular autoimmune syndromes. J Endocrinol Invest. 2018;41(1):91-98.
    1. Kahaly GJ, Frommer L. Autoimmune polyglandular diseases. Best Pract Res Clin Endocrinol Metab. 2019;33(6):101344.
    1. Brix TH, Kyvik KO, Christensen K, Hegedüs L. Evidence for a major role of heredity in Graves’ disease: a population-based study of two Danish twin cohorts. J Clin Endocrinol Metab. 2001;86(2):930-934.
    1. Strieder TG, Prummel MF, Tijssen JG, Endert E, Wiersinga WM. Risk factors for and prevalence of thyroid disorders in a cross-sectional study among healthy female relatives of patients with autoimmune thyroid disease. Clin Endocrinol (Oxf). 2003;59(3):396-401.
    1. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G. High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves’ disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. J Intern Med. 1991;229(5):415-420.
    1. Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160(5):661-666.
    1. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
    1. Diana T, Daiber A, Oelze M, et al. Stimulatory TSH-receptor antibodies and oxidative stress in Graves disease. J Clin Endocrinol Metab. 2018;103(10):3668-3677.
    1. Diana T, Olivo PD, Chang YH, Wüster C, Kanitz M, Kahaly GJ. Comparison of a novel homogeneous cyclic amp assay and a luciferase assay for measuring stimulating thyrotropin-receptor autoantibodies. Eur Thyroid J. 2020;9(2):67-72.
    1. Davies TF, Andersen S, Latif R, et al. Graves’ disease. Nat Rev Dis Primers. 2020;6(1):52.
    1. Kahaly GJ, Diana T, Olivo PD. TSH receptor antibodies: relevance & utility. Endocr Pract. 2020;26(1):97-106.
    1. Grebe SK, Kahaly GJ. Laboratory testing in hyperthyroidism. Am J Med. 2012;125(9):S2.
    1. de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med. 1989;149(3):526-532.
    1. Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990;70(2):453-460.
    1. Bartalena L, Burch HB, Burman KD, Kahaly GJ. A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf). 2016;84(1):115-120.
    1. Kahaly GJ, Olivo PD. Graves’ disease. N Engl J Med. 2017;376(2):184.
    1. Kahaly GJ, Diana T. TSH receptor antibody functionality and nomenclature. Front Endocrinol (Lausanne). 2017;8:28.
    1. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N. TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. Autoimmun Rev. 2012;12(2):107-113.
    1. Lytton SD, Li Y, Olivo PD, Kohn LD, Kahaly GJ. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins. Clin Exp Immunol. 2010;162(3):438-446.
    1. Leschik JJ, Diana T, Olivo PD, et al. Analytical performance and clinical utility of a bioassay for thyroid-stimulating immunoglobulins. Am J Clin Pathol. 2013;139(2):192-200.
    1. Li Y, Kim J, Diana T, Klasen R, Olivo PD, Kahaly GJ. A novel bioassay for anti-thyrotrophin receptor autoantibodies detects both thyroid-blocking and stimulating activity. Clin Exp Immunol. 2013;173(3):390-397.
    1. Araki N, Iida M, Amino N, et al. Rapid bioassay for detection of thyroid-stimulating antibodies using cyclic adenosine monophosphate-gated calcium channel and aequorin. Eur Thyroid J. 2015;4(1):14-19.
    1. Kahaly GJ. Bioassays for TSH receptor antibodies: Quo Vadis? Eur Thyroid J. 2015;4(1):3-5.
    1. Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ. Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid. 2015;25(2):169-175.
    1. Diana T, Li Y, Olivo PD, et al. Analytical performance and validation of a bioassay for thyroid-blocking antibodies. Thyroid. 2016;26(5):734-740.
    1. Diana T, Krause J, Olivo PD, et al. Prevalence and clinical relevance of thyroid stimulating hormone receptor-blocking antibodies in autoimmune thyroid disease. Clin Exp Immunol. 2017;189(3):304-309.
    1. Diana T, Wüster C, Kanitz M, Kahaly GJ. Highly variable sensitivity of five binding and two bio-assays for TSH-receptor antibodies. J Endocrinol Invest. 2016;39(10):1159-1165.
    1. Diana T, Wüster C, Olivo PD, et al. Performance and specificity of 6 immunoassays for TSH receptor antibodies: a multicenter study. Eur Thyroid J. 2017;6(5):243-249.
    1. Allelein S, Diana T, Ehlers M, et al. Comparison of a bridge immunoassay with two bioassays for thyrotropin receptor antibody detection and differentiation. Horm Metab Res. 2019;51(6):341-346.
    1. Lytton SD, Ponto KA, Kanitz M, Matheis N, Kohn LD, Kahaly GJ. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves’ orbitopathy. J Clin Endocrinol Metab. 2010;95(5):2123-2131.
    1. Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology. 2011;118(11):2279-2285.
    1. Diana T, Brown RS, Bossowski A, et al. Clinical relevance of thyroid-stimulating autoantibodies in pediatric Graves’ disease-a multicenter study. J Clin Endocrinol Metab. 2014;99(5):1648-1655.
    1. Ponto KA, Diana T, Binder H, et al. Thyroid-stimulating immunoglobulins indicate the onset of dysthyroid optic neuropathy. J Endocrinol Invest. 2015;38(7):769-777.
    1. Kampmann E, Diana T, Kanitz M, Hoppe D, Kahaly GJ. Thyroid stimulating but not blocking autoantibodies are highly prevalent in severe and active thyroid-associated orbitopathy: a prospective study. Int J Endocrinol. 2015;2015(1):678194.
    1. Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, König J. Thyroid stimulating antibodies are highly prevalent in Hashimoto’s thyroiditis and associated orbitopathy. J Clin Endocrinol Metab. 2016;101(5):1998-2004.
    1. Stożek K, Bossowski A, Ziora K, et al. Functional TSH receptor antibodies in children with autoimmune thyroid diseases. Autoimmunity. 2018;51(2):62-68.
    1. Kiefer FW, Klebermass-Schrehof K, Steiner M, et al. Fetal/neonatal thyrotoxicosis in a newborn from a hypothyroid woman with Hashimoto thyroiditis. J Clin Endocrinol Metab. 2017;102(1):6-9.
    1. Decallonne B, Martens PJ, Van den Bruel A, Vanhole C, Kahaly GJ. Graves Disease with thyroid-stimulating hormone receptor-blocking autoantibodies during pregnancy. Ann Intern Med. 2020;172(11):767-769.
    1. Mestman J. Fetal hyperthyroidism resulted from TSI in a mother with Hashimoto’s hypothyroidism. Clin Thyroidol. 2017;29(1):32-34.
    1. McKee A, Peyerl F. TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. Am J Manag Care. 2012;18(1):e1-14.
    1. Kahaly GJ, Bartalena L, Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective. Thyroid. 2011;21(6):585-591.
    1. Vitti P, Rago T, Mancusi F, et al. Thyroid hypoechogenic pattern at ultrasonography as a tool for predicting recurrence of hyperthyroidism after medical treatment in patients with Graves’ disease. Acta Endocrinol (Copenh). 1992;126(2):128-131.
    1. Hegedüs L. Thyroid ultrasound. Endocrinol Metab Clin North Am. 2001;30(2):339-360, viii.
    1. Erdoğan MF, Anil C, Cesur M, Başkal N, Erdoğan G. Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. Thyroid. 2007;17(3):223-228.
    1. Ralls PW, Mayekawa DS, Lee KP, et al. Color-flow Doppler sonography in Graves disease: “thyroid inferno”. AJR Am J Roentgenol. 1988;150(4):781-784.
    1. Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549-4558.
    1. Brito JP, Schilz S, Singh Ospina N, et al. Antithyroid drugs-the most common treatment for Graves’ disease in the United States: a nationwide population-based study. Thyroid. 2016;26(8):1144-1145.
    1. Bartalena L, Baldeschi L, Boboridis K, et al. ; European Group on Graves’ Orbitopathy (EUGOGO) . The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the management of Graves’ orbitopathy. Eur Thyroid J. 2016;5(1):9-26.
    1. Ma C, Xie J, Wang H, Li J, Chen S. Radioiodine therapy versus antithyroid medications for Graves’ disease. Cochrane Database Syst Rev. 2016;2:CD010094.
    1. Fanning E, Inder WJ, Mackenzie E. Radioiodine treatment for graves’ disease: a 10-year Australian cohort study. BMC Endocr Disord. 2018;18(1):94.
    1. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med. 1998;338(2):73-78.
    1. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992;326(26):1733-1738.
    1. Träisk F, Tallstedt L, Abraham-Nordling M, et al. ; Thyroid Study Group of TT 96 . Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab. 2009;94(10):3700-3707.
    1. Li HX, Xiang N, Hu WK, Jiao XL. Relation between therapy options for Graves’ disease and the course of Graves’ ophthalmopathy: a systematic review and meta-analysis. J Endocrinol Invest. 2016;39(11):1225-1233.
    1. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158(1):69-75.
    1. Davidson B, Soodak M, Neary JT, et al. The irreversible inactivation of thyroid peroxidase by methylmercaptoimidazole, thiouracil, and propylthiouracil in vitro and its relationship to in vivo findings. Endocrinology. 1978;103(3):871-882.
    1. Taurog A, Riesco G, Larsen PR. Formation of 3,3’-diiodothyronine and 3’,5’,3-triiodothyronine (reverse T3) in thyroid glands of rats and in enzymatically iodinated thyroglobulin. Endocrinology. 1976;99(1):281-290.
    1. Humar M, Dohrmann H, Stein P, et al. Thionamides inhibit the transcription factor nuclear factor-kappaB by suppression of Rac1 and inhibitor of kappaB kinase alpha. J Pharmacol Exp Ther. 2008;324(3):1037-1044.
    1. Tötterman TH, Karlsson FA, Bengtsson M, Mendel-Hartvig I. Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves’ disease. N Engl J Med. 1987;316(1):15-22.
    1. Zantut-Wittmann DE, Tambascia MA, da Silva Trevisan MA, Pinto GA, Vassallo J. Antithyroid drugs inhibit in vivo HLA-DR expression in thyroid follicular cells in Graves’ disease. Thyroid. 2001;11(6):575-580.
    1. Imamura M, Aoki N, Saito T, et al. Inhibitory effects of antithyroid drugs on oxygen radical formation in human neutrophils. Acta Endocrinol (Copenh). 1986;112(2):210-216.
    1. Weetman AP, Holt ME, Campbell AK, Hall R, McGregor AM. Methimazole and generation of oxygen radicals by monocytes: potential role in immunosuppression. Br Med J (Clin Res Ed). 1984;288(6416):518-520.
    1. Kim KA, von Zastrow M. Old drugs learn new tricks: insights from mammalian trace amine receptors. Mol Pharmacol. 2001;60(6):1165-1167.
    1. Jansson R, Dahlberg PA, Johansson H, Lindström B. Intrathyroidal concentrations of methimazole in patients with Graves’ disease. J Clin Endocrinol Metab. 1983;57(1):129-132.
    1. Visser TJ, van Overmeeren-Kaptein E. Study on the enzymatic 5’-deiodination of 3’,5’-diiodothyronine using a radioimmunoassay for 3’-iodothyronine. Biochim Biophys Acta. 1980;631(2):246-252.
    1. Kuiper GG, Kester MH, Peeters RP, Visser TJ. Biochemical mechanisms of thyroid hormone deiodination. Thyroid. 2005;15(8):787-798.
    1. Cooper DS. Antithyroid drugs. N Engl J Med. 2005;352(9):905-917.
    1. Cooper DS. Antithyroid drugs in the management of patients with Graves’ disease: an evidence-based approach to therapeutic controversies. J Clin Endocrinol Metab. 2003;88(8):3474-3481.
    1. Jansson R, Dahlberg PA, Lindström B. Comparative bioavailability of carbimazole and methimazole. Int J Clin Pharmacol Ther Toxicol. 1983;21(10):505-510.
    1. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98(11):4373-4381.
    1. Cooper DS, Laurberg P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol. 2013;1(3):238-249.
    1. Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am. 1993;22(2):263-277.
    1. Abraham P, Avenell A, McGeoch SC, et al. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;1:CD003420.
    1. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996;334(4):220-224.
    1. Pujol P, Osman A, Grabar S, et al. TSH suppression combined with carbimazole for Graves’ disease: effect on remission and relapse rates. Clin Endocrinol (Oxf). 1998;48(5):635-640.
    1. Rittmaster RS, Abbott EC, Douglas R, et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves’ disease. J Clin Endocrinol Metab. 1998;83(3):814-818.
    1. Glinoer D, de Nayer P, Bex M; Belgian Collaborative Study Group on Graves’ Disease . Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol. 2001;144(5):475-483.
    1. Okamoto Y, Tanigawa S, Ishikawa K, Hamada N. TSH receptor antibody measurements and prediction of remission in Graves’ disease patients treated with minimum maintenance doses of antithyroid drugs. Endocr J. 2006;53(4):467-472.
    1. Vitti P, Rago T, Chiovato L, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7(3):369-375.
    1. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR. Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest. 2002;25(2):152-157.
    1. Rotondi M, Cappelli C, Pirali B, et al. The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab. 2008;93(10):3985-3988.
    1. Azizi F, Malboosbaf R. Long-term antithyroid drug treatment: a systematic review and meta-analysis. Thyroid. 2017;27(10):1223-1231.
    1. Vos XG, Endert E, Zwinderman AH, Tijssen JG, Wiersinga WM. Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2016;101(4):1381-1389.
    1. Masiello E, Veronesi G, Gallo D, et al. Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management. J Endocrinol Invest. 2018;41(12):1425-1432.
    1. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2007;92(6):2157-2162.
    1. Brix TH, Lund LC, Henriksen DP, et al. Methimazole and risk of acute pancreatitis. Lancet Diabetes Endocrinol. 2020;8(3):187-189.
    1. Cooper D. The association between thionamides and acute pancreatitis. Clin Thyroidol 2020;32(7):327-329.
    1. Guo JY, Chang CL, Chen CC. Association between thionamides and acute pancreatitis: a case-control study. [Published online on June 10, 2020]. Thyroid. 2020. Doi: 10.1089/thy.2019.0589
    1. Tajiri J, Noguchi S, Murakami T, Murakami N. Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. Arch Intern Med. 1990;150(3):621-624.
    1. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab. 2013;98(12):4776-4783.
    1. Sheng WH, Hung CC, Chen YC, et al. Antithyroid-drug-induced agranulocytosis complicated by life-threatening infections. QJM. 1999;92(8):455-461.
    1. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19(6):559-563.
    1. Fibbe WE, Claas FH, Van der Star-Dijkstra W, Schaafsma MR, Meyboom RH, Falkenburg JH. Agranulocytosis induced by propylthiouracil: evidence of a drug dependent antibody reacting with granulocytes, monocytes and haematopoietic progenitor cells. Br J Haematol. 1986;64(2):363-373.
    1. Akamizu T, Ozaki S, Hiratani H, et al. Drug-induced neutropenia associated with anti-neutrophil cytoplasmic antibodies (ANCA): possible involvement of complement in granulocyte cytotoxicity. Clin Exp Immunol. 2002;127(1):92-98.
    1. Johnston A, Uetrecht J. Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis. Expert Opin Drug Metab Toxicol. 2015;11(2):243-257.
    1. Chen PL, Shih SR, Wang PW, et al. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. Nat Commun. 2015;6(7633):7633.
    1. Hallberg P, Eriksson N, Ibañez L, et al. ; EuDAC collaborators . Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016;4(6):507-516.
    1. Andrès E, Zimmer J, Mecili M, Weitten T, Alt M, Maloisel F. Clinical presentation and management of drug-induced agranulocytosis. Expert Rev Hematol. 2011;4(2):143-151.
    1. Balavoine AS, Glinoer D, Dubucquoi S, Wémeau JL. Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? Thyroid. 2015;25(12):1273-1281.
    1. Woeber KA. Methimazole-induced hepatotoxicity. Endocr Pract. 2002;8(3):222-224.
    1. Yang J, Li LF, Xu Q, et al. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. Thyroid. 2015;25(3):278-283.
    1. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol. 2014;78(3):619-629.
    1. Huang MJ, Liaw YF. Clinical associations between thyroid and liver diseases. J Gastroenterol Hepatol. 1995;10(3):344-350.
    1. Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid. 2017;27(3):315-389.
    1. Momotani N, Ito K, Hamada N, Ban Y, Nishikawa Y, Mimura T. Maternal hyperthyroidism and congenital malformation in the offspring. Clin Endocrinol (Oxf). 1984;20(6):695-700.
    1. Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC. Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. Eur J Obstet Gynecol Reprod Biol. 1994;54(3):159-163.
    1. Andersen SL, Andersen S, Vestergaard P, Olsen J. Maternal thyroid function in early pregnancy and child neurodevelopmental disorders: a Danish nationwide case-cohort study. Thyroid. 2018;28(4):537-546.
    1. Laurberg P, Andersen SL. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur J Endocrinol. 2014;171(1):R13-R20.
    1. Clementi M, Di Gianantonio E, Pelo E, Mammi I, Basile RT, Tenconi R. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet. 1999;83(1):43-46.
    1. Seo GH, Kim TH, Chung JH. Antithyroid drugs and congenital malformations: a nationwide Korean cohort study. Ann Intern Med. 2018;168(6):405-413.
    1. Andersen SL, Knøsgaard L, Olsen J, Vestergaard P, Andersen S. Maternal thyroid function, use of antithyroid drugs in early pregnancy, and birth defects. J Clin Endocrinol Metab. 2019;104(12):6040-6048.
    1. Andersen SL, Olsen J, Wu CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;24(10):1533-1540.
    1. Andersen SL, Andersen S. Timing of shift in antithyroid drug therapy and birth defects. Thyroid. 2019;29(1):155-156.
    1. Azizi F, Amouzegar A, Tohidi M, et al. Increased remission rates after long-term methimazole therapy in patients with Graves’ disease: results of a randomized clinical trial. Thyroid. 2019;29(9):1192-1200.
    1. Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab. 1993;76(6):1516-1521.
    1. Sato S, Noh JY, Sato S, et al. Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves’ disease patients with moderate to severe hyperthyroidism. Thyroid. 2015;25(1):43-50.
    1. Azizi F, Malboosbaf R. Safety of long-term antithyroid drug treatment? A systematic review. J Endocrinol Invest. 2019;42(11):1273-1283.
    1. Laurberg P, Berman DC, Andersen S, Bülow Pedersen I. Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid. 2011;21(9):951-956.
    1. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005;152(5):695-701.
    1. Elbers L, Mourits M, Wiersinga W. Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid. 2011;21(3):279-283.
    1. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid. 2015;25(12):1282-1290.
    1. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med. 2009;360(15):1574-1575.
    1. Biondi B, Bartalena L, Cooper DS, Hegedüs L, Laurberg P, Kahaly GJ. The 2015 European Thyroid Association Guidelines on diagnosis and treatment of endogenous subclinical hyperthyroidism. Eur Thyroid J. 2015;4(3):149-163.
    1. Gencer B, Collet TH, Virgini V, et al. ; Thyroid Studies Collaboration . Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040-1049.
    1. Collet TH, Gussekloo J, Bauer DC, et al. ; Thyroid Studies Collaboration . Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med. 2012;172(10):799-809.
    1. Blum MR, Bauer DC, Collet TH, et al. ; Thyroid Studies Collaboration . Subclinical thyroid dysfunction and fracture risk: a meta-analysis. JAMA. 2015;313(20):2055-2065.
    1. Zhyzhneuskaya S, Addison C, Tsatlidis V, Weaver JU, Razvi S. The natural history of subclinical hyperthyroidism in Graves’ disease: the rule of thirds. Thyroid. 2016;26(6):765-769.
    1. Kahaly GJ, Dillmann WH. Thyroid hormone action in the heart. Endocr Rev. 2005;26(5):704-728.
    1. Biondi B, Kahaly GJ. Cardiovascular involvement in patients with different causes of hyperthyroidism. Nat Rev Endocrinol. 2010;6(8):431-443.
    1. Bartalena L, Baldeschi L, Dickinson A, et al. ; European Group on Graves’ Orbitopathy (EUGOGO) . Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol. 2008;158(3):273-285.
    1. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD. Radioiodine-induced thyroid storm. Case report and literature review. Am J Med. 1983;75(2):353-359.
    1. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves’ disease. J Clin Endocrinol Metab. 2001;86(7):3016-3021.
    1. Ross DS. Radioiodine therapy for hyperthyroidism. N Engl J Med. 2011;364(6):542-550.
    1. Aung ET, Zammitt NN, Dover AR, Strachan MWJ, Seckl JR, Gibb FW. Predicting outcomes and complications following radioiodine therapy in Graves’ thyrotoxicosis. Clin Endocrinol (Oxf). 2019;90(1):192-199.
    1. Andrade VA, Gross JL, Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 1999;84(11):4012-4016.
    1. Teng CJ, Hu YW, Chen SC, et al. Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study. J Natl Cancer Inst. 2016;108(2):1-8.
    1. Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109(10):1972-1979.
    1. Hieu TT, Russell AW, Cuneo R, et al. Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. Endocr Relat Cancer. 2012;19(5):645-655.
    1. Ryödi E, Metso S, Jaatinen P, et al. Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab. 2015;100(10):3710-3717.
    1. Kitahara CM, Berrington de Gonzalez A, Bouville A, et al. Association of radioactive iodine treatment with cancer mortality in patients with hyperthyroidism. JAMA Intern Med. 2019;179(8):1034-1042.
    1. Kitahara CM, Preston DL, Sosa JA, Berrington de Gonzalez A. Association of radioactive iodine, antithyroid drug, and surgical treatments with solid cancer mortality in patients with hyperthyroidism. JAMA Netw Open. 2020;3(7):e209660.
    1. Gronich N, Lavi I, Rennert G, Saliba W. Cancer risk after radioactive iodine treatment for hyperthyroidism: a cohort study. Thyroid. 2020;30(2):243-250.
    1. De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016;388(10047):906-918.
    1. Randle RW, Bates MF, Long KL, Pitt SC, Schneider DF, Sippel RS. Impact of potassium iodide on thyroidectomy for Graves’ disease: implications for safety and operative difficulty. Surgery. 2018;163(1):68-72.
    1. Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E. What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol. 2013;20(2):660-667.
    1. Kandil E, Noureldine SI, Abbas A, et al. The impact of surgical volume on patient outcomes following thyroid surgery. Surgery. 2013;154(6):1346-1352; discussion 52-53.
    1. Hauch A, Al-Qurayshi Z, Randolph G, Kandil E. Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons. Ann Surg Oncol. 2014;21(12):3844-3852.
    1. Dralle H. Surgical assessment of complications after thyroid gland operations. Chirurg. 2015;86(1):70-77.
    1. Oltmann SC, Brekke AV, Schneider DF, Schaefer SC, Chen H, Sippel RS. Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. Ann Surg Oncol. 2015;22(3):952-958.
    1. Xing T, Hu Y, Wang B, Zhu J. Role of oral calcium supplementation alone or with vitamin D in preventing post-thyroidectomy hypocalcaemia: a meta-analysis. Medicine (Baltimore). 2019;98(8):e14455.
    1. Di Donna V, Santoro MG, de Waure C, et al. A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. Thyroid. 2014;24(12):1759-1764.
    1. Elfenbein DM, Schaefer S, Shumway C, Chen H, Sippel RS, Schneider DF. Prospective intervention of a novel levothyroxine dosing protocol based on body mass index after thyroidectomy. J Am Coll Surg. 2016;222(1):83-88.
    1. Taylor PN, Zhang L, Lee RWJ, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. Nat Rev Endocrinol. 2020;16(2):104-116.
    1. Diana T, Ponto KA, Kahaly GJ. Thyrotropin receptor antibodies and Graves’ orbitopathy. [Published online on August 04, 2020]. J Endocrinol Invest. 2020. Doi: 10.1007/s40618-020-01380-9
    1. Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves’ orbitopathy: the European Group on Graves’ Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol. 2006;155(3):387-389.
    1. Kahaly GJ, Diana T, Kanitz M, et al. Prospective trial of functional thyrotropin receptor antibodies in Graves disease. J Clin Endocrinol Metab. 2020;105(4):e1006-14.
    1. Kahaly GJ, Wüster C, Olivo PD, Diana T. High titers of thyrotropin receptor antibodies are associated with orbitopathy in patients with Graves disease. J Clin Endocrinol Metab. 2019;104(7):2561-2568.
    1. Marcocci C, Kahaly GJ, Krassas GE, et al. ; European Group on Graves’ Orbitopathy . Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364(20):1920-1931.
    1. Kahaly GJ. Management of moderately severe graves’ orbitopathy. In: Graves’ Orbitopathy - A Multidisciplinary Approach Questions and Answers. 3rd ed. Basel: Karger; 2017.
    1. Jespersen S, Nygaard B, Kristensen LØ. Methylprednisolone pulse treatment of Graves’ ophthalmopathy is not associated with secondary adrenocortical insufficiency. Eur Thyroid J. 2015;4(4):222-225.
    1. Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320-332.
    1. Zang S, Ponto KA, Pitz S, Kahaly GJ. Dose of intravenous steroids and therapy outcome in Graves’ orbitopathy. J Endocrinol Invest. 2011;34(11):876-880.
    1. Tanda ML, Bartalena L. Efficacy and safety of orbital radiotherapy for graves’ orbitopathy. J Clin Endocrinol Metab. 2012;97(11):3857-3865.
    1. Wiersinga WM, Kahaly GJ. Graves’ Orbitopathy a Multidisciplinary Approach. 3rd ed. Basel: Karger; 2017.
    1. Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726-738.
    1. Moshkelgosha S, So PW, Deasy N, Diaz-Cano S, Banga JP. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves’ orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology. 2013;154(9):3008-3015.
    1. Faßbender J, Holthoff HP, Li Z, Ungerer M. Therapeutic effects of short cyclic and combined epitope peptides in a long-term model of Graves’ disease and orbitopathy. Thyroid. 2019;29(2):258-267.
    1. Holthoff HP, Goebel S, Li Z, et al. Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves’ disease, tachycardia, and cardiac hypertrophy. Endocrinology. 2015;156(4):1577-1589.
    1. Holthoff HP, Li Z, Faßbender J, et al. Cyclic peptides for effective treatment in a long-term model of Graves disease and orbitopathy in female mice. Endocrinology. 2017;158(7):2376-2390.
    1. Hai YP, Lee ACH, Frommer L, Diana T, Kahaly GJ. Immunohistochemical analysis of human orbital tissue in Graves’ orbitopathy. J Endocrinol Invest. 2020;43(2):123-137.
    1. Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D, Ludgate M. Biological effects of thyrotropin receptor activation on human orbital preadipocytes. Invest Ophthalmol Vis Sci. 2006;47(12):5197-5203.
    1. Wang Y, Smith TJ. Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. Invest Ophthalmol Vis Sci. 2014;55(3):1735-1748.
    1. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity. 1993;16(4):251-257.
    1. Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol. 2008;181(6):4397-4405.
    1. Douglas RS, Gianoukakis AG, Kamat S, Smith TJ. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves’ disease may carry functional consequences for disease pathogenesis. J Immunol. 2007;178(5):3281-3287.
    1. Smith TJ, Janssen J. Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev. 2019;40(1):236-267.
    1. Minich WB, Dehina N, Welsink T, et al. Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J Clin Endocrinol Metab. 2013;98(2):752-760.
    1. Marinò M, Rotondo Dottore G, Ionni I, et al. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy. J Endocrinol Invest. 2019;42(4):471-480.
    1. Krieger CC, Place RF, Bevilacqua C, et al. TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab. 2016;101(6):2340-2347.
    1. Krieger CC, Perry JD, Morgan SJ, Kahaly GJ, Gershengorn MC. TSH/IGF-1 receptor cross-talk rapidly activates extracellular signal-regulated kinases in multiple cell types. Endocrinology. 2017;158(10):3676-3683.
    1. Krieger CC, Boutin A, Jang D, et al. Arrestin-β-1 physically scaffolds TSH and IGF1 receptors to enable crosstalk. Endocrinology. 2019;160(6):1468-1479.
    1. Marcus-Samuels B, Krieger CC, Boutin A, Kahaly GJ, Neumann S, Gershengorn MC. Evidence that Graves’ ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors. Thyroid. 2018;28(5):650-655.
    1. Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol. 2003;170(12):6348-6354.
    1. Chen H, Shan SJ, Mester T, Wei YH, Douglas RS. TSH-mediated TNFα production in human fibrocytes is inhibited by teprotumumab, an IGF-1R antagonist. PLoS One. 2015;10(6):e0130322.
    1. Chen H, Mester T, Raychaudhuri N, et al. Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab. 2014;99(9):E1635-E1640.
    1. Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748-1761.
    1. Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341-352.
    1. Smith TJ, Bartalena L. Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy? Eur J Endocrinol. 2019;181(5):D27-D43.
    1. Douglas RS, Kahaly GJ. Teprotumumab for active thyroid eye disease. Reply. N Engl J Med. 2020;382(20):1959-1960.
    1. Bartalena L, Fatourechi V. Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest. 2014;37(8):691-700.
    1. Fatourechi V. Thyroid dermopathy and acropachy. Best Pract Res Clin Endocrinol Metab. 2012;26(4):553-565.
    1. Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab. 2002;87(12):5435-5441.
    1. Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab. 2002;87(2):438-446.
    1. Okosieme OE, Taylor PN, Evans C, et al. Primary therapy of Graves’ disease and cardiovascular morbidity and mortality: a linked-record cohort study. Lancet Diabetes Endocrinol. 2019;7(4):278-287.
    1. Akamizu T. Thyroid storm: a Japanese perspective. Thyroid. 2018;28(1):32-40.
    1. Bartalena L, Chiovato L, Marcocci C, Vitti P, Piantanida E, Tanda ML. Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic. J Endocrinol Invest. 2020;43(8):1149-1151.
    1. Kaiser UB, Mirmira RG, Stewart PM. Our response to COVID-19 as Endocrinologists and Diabetologists. J Clin Endocrinol Metab. 2020;105(5):1299-1301.
    1. Puig-Domingo M, Marazuela M, Giustina A. COVID-19 and endocrine diseases. A statement from the European Society of Endocrinology. Endocrine. 2020;68(1):2-5.
    1. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90(9):5234-5240.
    1. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond). 2005;19(12):1286-1289.
    1. Ayabe R, Rootman DB, Hwang CJ, Ben-Artzi A, Goldberg R. Adalimumab as steroid-sparing treatment of inflammatory-stage thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(5):415-419.
    1. Allison AC. Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transplant Proc. 2002;34(7):2863-2866.
    1. Kahaly GJ, Riedl M, König J, et al. ; European Group on Graves’ Orbitopathy (EUGOGO) . Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 2018;6(4):287-298.
    1. Ye X, Bo X, Hu X, et al. Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves’ orbitopathy. Clin Endocrinol (Oxf). 2017;86(2):247-255.
    1. Lee ACH, Riedl M, Frommer L, Diana T, Kahaly GJ. Systemic safety analysis of mycophenolate in Graves’ orbitopathy. J Endocrinol Invest. 2020;43(6):767-777.
    1. Riedl M, Kuhn A, Krämer I, Kolbe E, Kahaly GJ. Prospective, systematically recorded mycophenolate safety data in Graves’ orbitopathy. J Endocrinol Invest. 2016;39(6):687-694.
    1. Sanders P, Young S, Sanders J, et al. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. 2011;46(2):81-99.
    1. Furmaniak J, Sanders J, Rees Smith B. Blocking type TSH receptor antibodies. Auto Immun Highlights. 2013;4(1):11-26.
    1. Marcinkowski P, Hoyer I, Specker E, et al. A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves’ orbitopathy. Thyroid. 2019;29(1):111-123.
    1. Jansson L, Vrolix K, Jahraus A, Martin KF, Wraith DC. Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice. Endocrinology. 2018;159(9):3446-3457.
    1. Pearce SHS, Dayan C, Wraith DC, et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: a phase I study. Thyroid. 2019;29(7):1003-1011.
    1. Cordoba F, Wieczorek G, Audet M, et al. A novel, blocking, Fc-silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant. 2015;15(11):2825-2836.
    1. Ristov J, Espie P, Ulrich P, et al. Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody. Am J Transplant. 2018;18(12):2895-2904.
    1. Kahaly GJ, Stan MN, Frommer L, et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-a proof-of-concept trial. J Clin Endocrinol Metab. 2020;105(3):696-704.
    1. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J Clin Endocrinol Metab. 2007;92(5):1769-1772.
    1. Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100(2):432-441.
    1. Salvi M, Vannucchi G, Currò N, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100(2):422-431.
    1. Stan MN, Salvi M. MANAGEMENT OF ENDOCRINE DISEASE: rituximab therapy for Graves’ orbitopathy - lessons from randomized control trials. Eur J Endocrinol. 2017;176(2):R101-R109.
    1. Pérez-Moreiras JV, Alvarez-López A, Gómez EC. Treatment of active corticosteroid-resistant graves’ orbitopathy. Ophthalmic Plast Reconstr Surg. 2014;30(2):162-167.
    1. Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. ; Tocilizumab in Graves Orbitopathy Study Group . Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am J Ophthalmol. 2018;195(1):181-190.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit